Navigation Links
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Date:11/22/2013

ron's products, product candidates, and research and clinical programs now underway or planned, including without limitation sarilumab; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates; ongoing regulatory obligations and oversight impacting Regeneron's research and clinical programs and business; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be cancelled or terminated without any further product success; and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended Decemb
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... YORK , July 6, 2015 E-QURE ... Chairman, will present live at VirtualInvestorConferences.com on July 9, ... EDT LINK: http://tinyurl.com/e-qure-presentation This ... are invited to ask the company questions in real-time ... the association,s "virtual trade booth." If attendees are not ...
(Date:7/6/2015)... Array BioPharma,s (NASDAQ:   ARRY) wholly-owned ... at the 2015 ESMO World Congress of Gastrointestinal ... data were shared from a Phase 1b trial ... 2 expansion of that trial testing the combination ... or without the addition of alpelisib (BYL719) ...
(Date:7/6/2015)... FRANCISCO, Calif. , July 6, 2015 ... pharmaceutical company, and Oculeve, a development-stage medical device company ... today announced that they have entered into an agreement ... transaction.  Under the terms of the agreement, Allergan will ... commercialization milestone payments related to Oculeve,s lead development program ...
Breaking Medicine Technology:E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced ... gout will be reviewed by the Arthritis Advisory Committee appointed ... 5, 2009 as required for a drug of a new ... the FDA on October 31, 2008 seeking approval to market ...
... 28 Cell Therapeutics (CTI),(Nasdaq and MTA: ... from its pivotal phase III EXTEND (PIX301) ... relapsed aggressive non-Hodgkin,s lymphoma,(NHL) treated with pixantrone ... survival, compared with other,single-agent chemotherapeutic agents ...
Cached Medicine Technology:Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 2Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 3Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 4Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial 2Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial 3Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial 4
(Date:7/6/2015)... Vancouver, BC (PRWEB) , ... July 06, 2015 , ... ... has received the UBC 2014-2015 Post Graduate Teaching Award on behalf of the department ... Endocrinology is a very exciting field to be practicing in. The technology is changing ...
(Date:7/6/2015)... Irvine, CA (PRWEB) , ... July 06, 2015 ... ... for disease prevention in southern California, has partnered with Woodbridge Walk-In Urgent Care ... disease, cancer, stroke and other serious medical conditions. Screenings are affordable and accurate ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Health care ... the ability of the medical field to access and use this “Big Data” to ... MD, President and Chief Executive Officer of the Mount Sinai Health System in New ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... In a ... learn how to reduce their risk of having a fracture through the bone health ... Fractures Awareness Day. , “We are participating because our residents need this information to ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... World renowned ... the opportunity to achieve their ideal appearance through comprehensive treatment solutions. Individuals that want ... with the doctor and receive a plan that resolves each of their needs. ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:National Bone Health Screening and Awareness Day 2Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2
... of time between pregnancies are at an increased risk for ... had given birth twice between 1992 and 1998. Results of ... more likely to become pregnant again in less than six ... 20 years old, smoke, and live in a socially and ...
... usually prescribe antibiotics for problems like pneumonia, but ... may also protect against strokes. ,How could a ... involves the blockage of blood vessels supplying the ... blood vessels rupture and block blood flow to ...
... of anxiety and became a cultural icon, is 40 years ... stubborn streak of chemist Leo Sternbach, who refused to quit ... develop a tranquilizer to compete with a rival company's drug. ... he got the results: The compound made animals relaxed and ...
... entering the "death" phase as mortality outstrips new infections, ... the world's worst -- and this is just the ... government has been criticized for its lackluster approach to ... million South Africans.,Activists have also called on the government ...
... what is believed to be Britain's first genetically-selected baby ... ,The new baby, named Jamie, was delivered by Caesarean ... an IVF embryo, to his four-year-old brother Charlie. Charlie ... traveled to the United States for treatment after being ...
... the risk of breast cancer recurrence in post-menopausal ... are drugs that block the conversion of precursor ... inhibitors block the conversion of precursor molecules into ... study, coordinated through the National Surgical Adjuvant Breast ...
Cached Medicine News:Health News:Valium hits 40 years old, anxiety-free 2Health News:Lowering Risk of Breast Cancer Recurrence 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: